학술논문
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial
Document Type
Article
Author
Marson, Anthony; Burnside, Girvan; Appleton, Richard; Smith, Dave; Leach, John Paul; Sills, Graeme; Tudur-Smith, Catrin; Plumpton, Catrin; Hughes, Dyfrig A; Williamson, Paula; Baker, Gus A; Balabanova, Silviya; Taylor, Claire; Brown, Richard; Hindley, Dan; Howell, Stephen; Maguire, Melissa; Mohanraj, Rajiv; Smith, Philip E; Lanyon, Karen; Manford, Mark; Chitre, Manali; Parker, Alasdair; Swiderska, Nina; Appleton, Richard; Pauling, James; Hughes, Adrian; Gupta, Rajat; Hanif, Sadia; Awadh, Mostafa; Ragunathan, Sharmini; Cable, Nicola; Cooper, Paul; Hindley, Daniel; Rakshi, Karl; Molloy, Sophie; Reuber, Markus; Ayonrinde, Kunle; Wilson, Martin; Saladi, Satyanarayana; Gibb, John; Funston, Lesley-Ann; Cassidy, Damhait; Boyd, Jonathan; Ratnayaka, Mal; Faza, Hani; Sadler, Martin; Al-Moasseb, Hassan; Galtrey, Clare; Wren, Damien; Olabi, Anas; Fuller, Geraint; Khan, Muhammed; Kallappa, Chetana; Chinthapalli, Ravi; Aji, Baba; Davies, Rhys; Foster, Kathryn; Hitiris, Nikolas; Maguire, Melissa; Hussain, Nahin; Dowson, Simon; Ellison, Julie; Sharrack, Basil; Gandhi, Vandna; Powell, Rob; Tittensor, Phil; Summers, Beatrice; Shashikiran, Sastry; Dison, Penelope J; Samarasekera, Shanika; McCorry, Doug; White, Kathleen; Nithi, Kannan; Richardson, Martin; Brown, Richard; Page, Rupert; Deekollu, David; Slaght, Sean; Warriner, Stephen; Ahmed, Mansoor; Chaudhuri, Abhijit; Chow, Gabriel; Artal, Javier; Kucinskiene, Danute; Sreenivasa, Harish; Velmurugan, Singara; Zipitis, Christos S; McLean, Brendan; Lal, Vaithianathar; Gregoriou, Angelous; Maddison, Paul; Pickersgill, Trevor; Anderson, Joseph; Lawthom, Charlotte; Howell, Stephen; Whitlingum, Gabriel; Rakowicz, Wojtek; Kinton, Lucy; McLellan, Alisa; Vora, Nitish; Zuberi, Sameer; Kelso, Andrew; Hughes, Imelda; Martland, John; Emsley, Hedley; de Goede, Christian; Singh, RP; Moor, Carl-Christian; Aram, Julia; Mohanraj, Rajiv; Sakthivel, Kumar; Nelapatla, Suresh; Rittey, Chris; Pinto, Ashwin; Leach, John Paul; Cock, Hannah; Richardson, Anna; Houston, Erika; Cooper, Christopher; Lawson, Geoff; Massarano, Albert; Burness, Christine; Marson, Anthony; Smith, Dave; Wieshmann, Udo; Dey, Indranil; Sivakumar, Puthuval; Yeung, Lap-Kong; Smith, Philip; Bentur, Hemalata; Heafield, Tom; Mathew, Anna; Smith, David; Jauhari, Praveen
Source
The Lancet; April 2021, Vol. 397 Issue: 10282 p1375-1386, 12p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Valproate is a first-line treatment for patients with newly diagnosed idiopathic generalised or difficult to classify epilepsy, but not for women of child-bearing potential because of teratogenicity. Levetiracetam is increasingly prescribed for these patient populations despite scarcity of evidence of clinical effectiveness or cost-effectiveness. We aimed to compare the long-term clinical effectiveness and cost-effectiveness of levetiracetam compared with valproate in participants with newly diagnosed generalised or unclassifiable epilepsy.